glp 1 and diabetic retinopathy The Link between GLP-1 Drugs Is Not So Clear | AAO 2024 Updated guidance from the PCDS

Wegovy, which contains semaglutide, is a GLP-1 agonist approved for weight loss and reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight

Our physician reviews medication options with you during your consultation

These variables meaningfully influence both efficacy and safety, including cardiovascular risk, thrombotic events, and metabolic response

When used as part of a broader treatment plan, tirzepatide can facilitate substantial weight loss and improve health outcomes

Bioglutide's potential is high but entirely unvalidated at this stage